(Updates with Novartis statement throughout.)
Novartis (NVS) said Thursday it will close its MorphoSys sites in Germany and the United States by the end of 2025, impacting about 330 jobs.
The drugmaker said the decision is part of its strategic evaluation of its evolving research and development portfolio, focusing on prioritizing scientific expertise and resources for key programs.
It added that the closure is also influenced by the extended follow-up time required to determine the approval pathway for pelabresib, a treatment for myelofibrosis.
NVS shares were edging 0.6% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。